Skip to main content

Advertisement

SpringerLink
Log in

Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents

  • Review Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background The discovery of antibiotics several decades ago was a defining moment in history. They were used to treat previously incurable diseases and save many lives. However, the use of antibiotics is not benign. Antibiotic resistance occurs due to the natural evolution of bacteria and gene transfer between bacteria via vertical and horizontal routes, resulting in protective mechanisms that render antibacterial agents ineffective. Aim of the review To list and describe current, novel pipeline antibiotics indicated for multidrug-resistant gram-negative bacteria. This review discusses the limited number of novel pipeline drugs available to combat the rapidly increasing number of multidrug-resistant bacteria and the need for initiatives to research and discover more novel antibiotics. Method A search of MEDLINE/PubMed using the search terms antibacterial pipeline OR antibiotic pipeline including publications between 1 January 2018 through 23 January 2020 resulted in 230 items. The results obtained were narrowed by adding the search term AND multi-drug resistant which resulted in 12 items. Then, ClinicalTrials.gov was searched for phase 2–3 “interventional” trials registered between 1 January 2018 and 23 January 2020 with the status “recruiting” or “completed” function and including World Health Organization-defined priority pathogens in the “condition or disease” field. The search process was then completed by introducing the term antibacterial agents in the “other terms” field. The trials search and selection resulted in 13 items. Relevant English-language studies and those conducted in humans were considered. Those drugs belonging to new antibiotic classes or to antibiotic classes already known but with new chemical structure were defined as “novel antibiotics”. Results The studies selected and reviewed were those referring to a novel antibiotics. Thus, from MEDLINE/PubMed, we found only 1 item referred to a novel chemical class (Murepavadin n = 1). From ClinicalTrials.gov a total of 4 citations were identified (Ftortiazinon n = 1, Zoliflodacin n = 1, Gepotidacin n = 1, ETX2514 + sulbactam n = 1). Conclusion The antibiotics annually approved by the Food and Drug Administration (FDA) mostly belong to existing classes of antibiotics and have specific indications, limiting their use in many multidrug-resistant infections. There are limited novel drug classes targeting gram-negative infections in the pipeline. Providers must be vigilant with the use of current antibiotics, especially until research and development (R&D) advancements are made.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Infectious Diseases Society of America (IDSA), Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(Suppl 5:):S397–428.

    Article  Google Scholar 

  2. Högberg LD, Heddini A, Cars O. The global need for effective antibiotics: challenges and recent advances. Trends Pharmacol Sci. 2010;31(11):509–15.

    Article  Google Scholar 

  3. Kish T. New antibiotics in development target highly resistant gram-negative organisms. Pharm Ther. 2018;43(2):116–20.

    Google Scholar 

  4. World Health Organization (WHO). Antibiotic resistance. http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/. Accessed 28 April 2020.

  5. Centers for Disease Control and Prevention (CDC). Antibiotic/Antimicrobial Resistance (AR/AMR). Centers for Disease Control and Prevention (CDC). https://www.cdc.gov/drugresistance/index.html. Accessed 28 April 2020.

  6. European Centre for Disease Prevention and Control (ECDC). The bacterial challenge: time to react. European Centre for Disease Prevention and Control (ECDC). https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf. Accessed 28 April 2020.

  7. Thorpe KE, Joski P, Johnston KJ. Antibiotic-resistant infection treatment costs have doubled since 2002, now exceeding $2 billion annually. Health Aff (Millwood). 2018;37(4):662–9.

    Article  Google Scholar 

  8. Fernandes P. The global challenge of new classes of antibacterial agents: an industry perspective. Curr Opin Pharmacol. 2015;24:7–11.

    Article  CAS  Google Scholar 

  9. Tufts Center for the Study of Drug Development (CSDD). Tufts CSDD Assessment of Cost to Develop and Win Marketing Approval for a New Drug Now Published. Tufts Center for the Study of Drug Development (CSDD). https://www.globenewswire.com/news-release/2016/03/10/1187518/0/en/Tufts-Center-for-the-Study-of-Drug-Development-Assessment-of-Cost-to-Develop-and-Win-Marketing-Approval-for-a-New-Drug-Now-Published.html. Accessed 28 April 2020.

  10. European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report 2016 – Infectious disease surveillance summary, EU/EEA, 2014 data. European Centre for Disease Prevention and Control (ECDC). https://www.ecdc.europa.eu/en/infectious-diseases-public-health/surveillance-and-disease-data/annual-epidemiological-reports. Accessed 28 April 2020.

  11. World Health Organization (WHO). WHO publishes list of bacteria for which new antibiotics are urgently needed. World Health Organization (WHO). http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/. Accessed 28 April 2020.

  12. US Food and Drug Administration (FDA). FDA Approved Drug Products. US Food and Drug Administration (FDA). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 28 April 2020.

  13. Xtoro [package insert]. Fort Worth, Texas: Alcon Laboratories, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206307s000lbl.pdf. 2014 Nov.

  14. Zerbaxa [package insert]. Lexington, MA: Cubist Pharmaceuticals U.S. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf. 2016 Oct.

  15. Avycaz [package insert]. Verona, 37135 Italy: GlaxoSmithKline Manufacturing S.p.A. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf. 2018 Feb.

  16. Baxdela [package insert]. Lincolnshire, Illinois: Melinta Therapeutics, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf. 2017 June.

  17. Vabomere [package insert]. Teramo, 64100, Italy: Facta Farmaceutici, S.p.A.. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209776lbl.pdf. 2017 Aug.

  18. Solosec [package insert]. Newark, NJ: Symbiomix Therapeutics LLC. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209363s000lbl.pdf. 2017 Oct.

  19. Zemdri [package insert]. South San Francisco, CA: Achaogen, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s000lbl.pdf. 2018 June.

  20. Xerava [package insert]. Watertown, MA: Tetraphase Pharmaceuticals, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf. 2018 Aug.

  21. Nuzyra [package insert]. Boston, MA: Paratek Pharmaceuticals, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf. 2018 Oct.

  22. Recarbrio [package insert].Whitehouse Station, NJ: Merck & Co. Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf. 2019 Jul.

  23. Xenleta [package insert]. King of Prussia, PA: Nabriva Pharmaceuticals US Inc. https://www.xenleta.com/pdf/xenleta-prescribing-information.pdf. 2019 Aug.

  24. Fetroja [package insert]. Florham Park, NJ: Shionogi US Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf. 2019 Nov.

  25. Coates RMA, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011;163:184–94.

    Article  CAS  Google Scholar 

  26. RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI (GAMECHANGER). https://clinicaltrials.gov/ct2/show/NCT03869437?cond=cefiderocol&draw=2&rank=2. Accessed 28 April 2020.

  27. Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017;2:17104.

    Article  Google Scholar 

  28. Study to evaluate the efficacy and safety of intravenous sulbactam-ETX2514 in the treatment of patients with infections caused by Acinetobacter Baumannii-calcoaceticus Complex (ATTACK). https://clinicaltrials.gov/ct2/show/NCT03894046. Accessed 28 April 2020.

  29. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Geneva: World Health Organization; 2017 (WHO/EMP/IAU/2017.12). https://apps.who.int/iris/bitstream/handle/10665/258965/%20WHO-EMP-IAU-2017.11-eng.pdf;jsessionid=17F40BB39895CFB4CC1967D672F218D1?sequence=1. Accessed 28 April 2020.

  30. Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea. https://clinicaltrials.gov/ct2/show/NCT02257918?term=NCT02257918&rank=1. Accessed 28 April 2020.

  31. Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep. 2015;5:11827.

    Article  CAS  Google Scholar 

  32. Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA. In Vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant gram-positive and fastidious gram-negative pathogens. Antimicrob Agents Chemother. 2015;59(10):6053–63.

    Article  CAS  Google Scholar 

  33. Zoliflodacin in Uncomplicated Gonorrhoea. https://clinicaltrials.gov/ct2/show/NCT03959527?term=Zoliflodacin&draw=2&rank=2. Accesses 28 April 2020.

  34. A study evaluating efficacy and safety of gepotidacin compared with ceftriaxone plus azithromycin in the treatment of uncomplicated urogenital gonorrhea. https://clinicaltrials.gov/ct2/show/NCT04010539. Accessed 28 April 2020.

  35. Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis. 2018;67(4):504–12.

    Article  CAS  Google Scholar 

  36. A dose-ranging study evaluating the efficacy, safety, and tolerability of GSK2140944 in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria Gonorrhoeae. https://clinicaltrials.gov/ct2/show/NCT02294682?term=NCT02294682&rank=1. Accessed 28 April 2020.

  37. Dose-ranging study of GSK2140944 in the treatment of subjects with suspected or confirmed gram-positive acute bacterial skin and skin structure infections. https://clinicaltrials.gov/ct2/show/NCT02045797?term=NCT02045797&rank=1. Accessed 28 April 2020.

  38. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010;466:935–40.

    Article  Google Scholar 

  39. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, et al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother. 2016;60:1918–23.

    Article  CAS  Google Scholar 

  40. Safety and efficacy study of ftortiazinon in the treatment of patients with complicated urinary tract infections caused by P. Aeruginosa. https://clinicaltrials.gov/ct2/show/NCT03638830. Accessed 28 April 2020.

  41. Kunda M, Voronina O, Sharapova N, Ryzhova N, Aksenova E, Gintsburg A. Virulence factors of Achromobacter ruhlandii important for host pathogen interaction. [abstract]. https://2018.febscongress.org/abstract_preview.aspx?idAbstractEnc=4424170094091096095092424170. Accessed 28 April 2020.

  42. Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas (PRISM-UDR). https://clinicaltrials.gov/ct2/show/NCT03582007?cond=murepavadin&draw=2&rank=1. Accessed 28 April 2020.

  43. Pivotal study in VAP suspected or confirmed to be due to Pseudomonas Aeruginosa (PRISM-MDR). https://clinicaltrials.gov/ct2/show/NCT03409679?cond=murepavadin&draw=2&rank=2. Accessed 28 April 2020.

  44. Martin-Loeches I, Dale GE, Torres A. Murepavadin: a new antibiotic class in the pipeline. Expert Rev Anti Infect Ther. 2018;16(4):259–68.

    Article  CAS  Google Scholar 

  45. Polyphor Ltd, Hegenheimermattweg 125, CH-4123 Allschwil,Switzerland, 17 July 2020. https://www.polyphor.com/news/corporate-news-details/?newsid=1800485. Accessed 10 June 2020.

  46. Reen FJ, Gutiérrez-Barranquero JA, Parages ML, O´Gara F. Coumarin: a novel player in microbial quorum sensing and biofilm formation inhibition. Appl Microbiol Biotechnol. 2018;102:2063–73.

    Article  CAS  Google Scholar 

  47. Dolatabadi S, Moghadam HN, Mahdavi-Ourtakand M. Evaluating the anti-biofilm and antibacterial effects of Juglans regia L. extracts against clinical isolates of Pseudomonas aeruginosa. Microb Pathog. 2018;118:285–9.

    Article  Google Scholar 

  48. Kotb A, Abutaleb NS, Seleem MA, Hagras M, Mohammad H, Bayoumi A, et al. Phenylthiazoles with tert-Butyl side chain: metabolically stable with anti-biofilm activity. Eur J Med Chem. 2018;151:110–20.

    Article  CAS  Google Scholar 

  49. Venter H, Mowla R, Ohene-Agyei T, Ma S. RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Front Microbiol. 2015;6:377.

    Article  Google Scholar 

  50. Xu Z, Flavin MT, Flavin J. Combating multidrug-resistant gram-negative bacterial infections. Expert Opin Investig Drugs. 2014;23(2):163–82.

    Article  CAS  Google Scholar 

  51. Chaudhary AS. A review of global initiatives to fight antibiotic resistance and recent antibiotics’ discovery. Acta Pharm Sin B. 2016;6(6):552–6.

    Article  Google Scholar 

  52. Generating Antibiotic Incentives Now. Department of Health and Human Services. Food and Drug Administration (FDA). https://www.fda.gov/media/110982/download. Accessed 28 April 2020.

  53. Paphitou NI. Antimicrobial resistance: action to combat the rising microbial challenges. Int J Antimicrob Agents. 2013;42S:S25–8.

    Article  Google Scholar 

  54. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A. 2018;115(15):E3463–70.

    Article  CAS  Google Scholar 

  55. Global action plan on antimicrobial resistance. World Health Organization (WHO). https://www.who.int/antimicrobial-resistance/global-action-plan/en/. Accessed 28 April 2020.

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Via E. Tricomi n. 5, 90127, Palermo, Italy

    A. Provenzani & P. Polidori

  2. School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA

    A. R. Hospodar, A. L. Meyer, E. Y. Hwang & C. M. Butrus

  3. School of Specialization in Hospital Pharmacy, University of Palermo, 90133, Palermo, Italy

    D. Leonardi Vinci

Authors
  1. A. Provenzani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. R. Hospodar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. L. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Leonardi Vinci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Y. Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. M. Butrus
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Polidori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Provenzani.

Ethics declarations

Author disclosures

All authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Conflicts of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Provenzani, A., Hospodar, A.R., Meyer, A.L. et al. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents. Int J Clin Pharm 42, 1016–1025 (2020). https://doi.org/10.1007/s11096-020-01089-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-020-01089-y

Keywords

Search

Navigation